Aptamer-labeled PLGA nanoparticles for targeting cancer cells

Aravind, Athulya; Varghese, Saino Hanna; Veeranarayanan, Srivani; Mathew, Anila; Nagaoka, Yutaka; Iwai, Seiki; Fukuda, Toshio; Hasumura, Takashi; Yoshida, Yasuhiko; Maekawa, Taira; Kumar, D. Sakthi

doi:10.1007/s12645-011-0024-6

Cited by 48 publications

(29 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…111 Researchers are trying to limit the dose of chemotherapeutic drugs by targeting the specific tumor cells without exposing the normal cells to the toxic effects of drug. 112 One of the landmarks in this regard is the development of nanocarriers that hold a great promise to enhance the therapeutic effectiveness and safety profile of conventional chemotherapeutic agents. These drug-loaded nanocarriers are capable of delivering antitumor chemotherapeutics to the tumor sites either by exploiting the pathophysiology of tumors or by decorating them with site-specific ligands.…”

mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,121

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,121

481

View full text Add to dashboard Cite

show abstract

“…Aravind et al [3] -MUC1 Apt/herceptin (monoclonal antibody, MAb)/ wheat germ agglutinin (WGA)/ AS1411 Apt/transferrin (Tf) Yu et al [88]/Mattu et al [55]/Mo and Lim [58,59], Wang et al [81]/Aravind et al [4,5]/Sahoo and Labhasetwar [68], Sahoo et al [67], Shah et al [72] Doxorubicin (DOX)…”

Section: As1411 Aptmentioning

confidence: 99%

“…Apts, usually attached to the surface of PLGA nanocarriers via the EDC/NHS technique, have been successfully employed as active targeting agents to enhance drug delivery to prostate cancer cells [25,16,21,32], breast cancer cells [88,3,5], hepatic carcinoma cells [90], and malignant human glial cell lines [33,3,4].…”

Section: Nucleotidesmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Engineering Approaches in the Development of PLGA-Based Nanomedicines

El-Hammadi¹,

Arias²

2015

Handbook of Nanoparticles

View full text Add to dashboard Cite

Drug molecules often display little affinity for nonhealthy tissues and/or cells, leading to inefficiency, and high incidence of severe side effects. To face the problem, numerous strategies have been postulated, i.e., chemical modifications to the drug molecule, and proper engineering of drug nanocarriers. In this line, the introduction of poly(D,L-lactide-co-glycolide) nanoparticles in the drug delivery arena has been hypothesized to optimize drug biodistribution and concentration into the targeted site, thus improving the therapeutic effect while reducing the associated drug toxicity. Recent advances in the field have been devoted to the optimization of the in vivo fate and effectiveness of poly(D,L-lactide-co-glycolide)-based drug nanocarriers, i.e., by passive targeting strategies based on the functionalization of the particle surface with special biomolecules, and/or active targeting stratagems thanks to modifications leading to stimuliresponsive nanoparticles. In this chapter, we analyze the current state of the art and future perspectives in the formulation of poly(D,L-lactide-co-glycolide)-based nanomedicines against severe diseases.

show abstract

“…[22][23][24] Paclitaxel (PTX), which is an anticancer drug with a broad spectrum, has previously been used to encapsulate PLGA polymers. [25][26][27] We also selected an A10-3.2 aptamer having merely 39 nucleotides as the targeting agent, which likely binds the intended proteins using optimal specificity and similarity, thus modulating the function of the target protein. [28][29][30] Aptamers, with stable structures and little immunogenicity, 31 can be chemically synthesized and stabilized.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-<em>co</em>-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Wu¹,

Wang²,

Wang³

et al. 2017

IJN

View full text Add to dashboard Cite

In the current study, we synthesized prostate cancer-targeting poly(lactide- co -glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy.

show abstract

Aptamer-labeled PLGA nanoparticles for targeting cancer cells

Cited by 48 publications

References 48 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Advanced Engineering Approaches in the Development of PLGA-Based Nanomedicines

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-<em>co</em>-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Contact Info

Product

Resources

About